Skip to main content
Premium Trial:

Request an Annual Quote

BioNanomatrix Changes Name to BioNano Genomics

Premium

BioNanomatrix has changed its name to BioNano Genomics, the company said this week.

Through the name change, the firm wants to communicate "its position as a solution provider for genomics researchers."

The company, originally based in Philadelphia but now headquartered in San Diego, has been developing a nanochannel platform, called NanoAnalyzer, to visualize single molecules of DNA. Its first applications are expected to be in de novo genome assembly and in structural variation analysis.

Earlier this year, BioNano Genomics raised $23.3 million in a Series B financing round, appointed a new president and CEO, and moved its headquarters (IS 6/21/2011).

It plans to launch the NanoAnalyzer commercially in 2012.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.